Top

Gepubliceerd in:

01-09-2012 | Artikelen

Symptoomdimensiescores zijn geassocieerd met progressieve hersenvolumeveranderingen bij schizofrenie

Auteurs: Mw. drs. G. Collin, mw. dr. N. E. M. van Haren, dr. H. G. Schnack, mw. prof. dr. H. E. Hulshoff Pol, mw. dr. W. Cahn, prof. dr. E. M. Derks

Gepubliceerd in: Neuropraxis | Uitgave 4/2012

Samenvatting

Schizofrenie is een progressieve hersenziekte: in de loop van de ziekte is er een voortschrijdend verlies van hersenweefsel. Er is echter aanzienlijke variatie binnen patiënten wat betreft de mate van progressie. Schizofreniepatiënten verschillen onderling eveneens sterk qua symptomatologie. Het is vooralsnog onbekend of die heterogeniteit op klinisch en biologisch vlak aan elkaar gerelateerd zijn. Als er een relatie bestaat, zou dit impliceren dat er mogelijk afzonderlijke neuropathologische mechanismen ten grondslag liggen aan verschillende klinische aspecten van schizofrenie. Onderzoek naar deze relatie zou de detectie van uiteenlopende neuropathologische en genetische factoren in schizofrenie kunnen faciliteren.

vorige artikel Elektroconvulsietherapie (ECT) als behandeling voor depressie bij dementerenden?1

volgende artikel Werkomgeving en cognitieve veroudering bij leraren: eencase-controle-studie gebaseerd op de Maastrichtse VerouderingsStudie

Andreasen, N.C., Flaum, M. & Arndt, S. (1992). The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology.Archives of General Psychiatry, 49,8, 615–623.PubMedCrossRef

Andreasen, N.C., Nopoulos, P., Magnotta, V., Pierson, R., Ziebell, S. & Ho., B.-C., (2011). Progressive brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia.Biological Psychiatry, 70,7, 672–679.PubMedCrossRef

Andreasen, N.C., Paradiso, S. & O’Leary, D.S. (1998). “Cognitive dysmetria” as an integrative theory of schizophrenia: a dysfunction in cortical-subcortical-cerebellar circuitry?Schizophrenia Bulletin, 24,2, 203–218.PubMedCrossRef

Bowden, N.A., Scott, R.J. & Tooney, P.A. (2007). Altered expression of regulator of G-protein signalling 4 (RGS4) mRNA in the superior temporal gyrus in schizophrenia.Schizophrenia Research, 89,1-3, 165– 168.PubMedCrossRef

Brouwer, R.M., Hulshoff Pol, H.E. & Schnack, H.G. (2010). Segmentation of MRI brain scans using non-uniform partial volume densities.NeuroImage, 49, 1, 467–477.PubMedCrossRef

Buchanan, R.W. & Carpenter, W.T. (1997). The neuroanatomies of schizophrenia.Schizophrenia Bulletin, 23,3, 367–372.PubMedCrossRef

Cahn, W., Rais, M., Stigter, F.P., Haren, N.E.M. van, Caspers, E., Hulshoff Pol, H.E., Xu, Z., Schnack, H.G. & Kahn, R.S. (2009).Psychosis and brain volume changes during the first five years of schizophrenia.European Neuropsychopharmacology, 19,2, 147–151.PubMedCrossRef

Collin, G., Derks, E.M., Haren, N.E.M. van, Schnack, H.G., Hulshoff Pol, H.E., Kahn, R.S. & Cahn, W. (2012). Symptom dimensions are associated with progressive brain volume changes in schizophrenia.Schizophrenia Research, 138,2-3, 171–176.PubMedCrossRef

DeLisi L.E., Hoff A.L., Sakuma M., Kushner M., Lee G., Kantawala K., Shedlack K., Smith A.M., Tew W. & Grimson R. (1995). A prospective follow-up study of brain morphology and cognition in 1st episode schizophrenic patients.Biological Psychiatry, 38, 349–360.PubMedCrossRef

DeLisi, L.E., Grimson, R., Sakuma, M., Tew, W., Kushner, M., Hoff, A.L. (1997). Schizophrenia as a chronic active brain process: A study of progressive brain structural change subsequent to the onset of schizophrenia.Psychiatry Research, 74, 129–140.CrossRef

DeLisi, L.E., Sakuma, M., Ge, S. & Kushner, M. (1998). Association of brain structural change with the heterogeneous course of schizophrenia from early childhood through five years subsequent to a first hospitalization.Psychiatry Research, 84,2-3, 75–88.CrossRef

Derks, E.M., Allardyce, J., Boks, M.P., Vermunt, J.K., Hijman, R. & Ophoff, R.A. (2010). Kraepelin Was Right: A Latent Class Analysis of Symptom Dimensions in Patients and Controls.Schizophrenia Bulletin, (September 30): 1–11. doi:10.1093/schbul/sbq103.

Dibben, C.R.M., Rice, C., Laws, K. & McKenna, P.J. (2009). Is executive impairment associated with schizophrenic syndromes? A metaanalysis.Psycholical Medicine, 39,3, 381–392.CrossRef

Flynn, J.R. (2009). The WAIS-III and WAIS-IV: Daubert motions favor the certainly false over the approximately true.Applied Neuropsychology, 16,2, 98–104.PubMedCrossRef

Gunduz-Bruce, H. (2009). The acute effects of NMDA antagonism: from the rodent to the human brain.Brain Research Review, 60,2, 279–286.CrossRef

Haren, N.E.M. van, Hulshoff Pol, H.E., Schnack, H.G., Cahn, W., Brans, R., Carati, I., Rais, M. & Kahn, R.S. (2008). Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood.Biological Psychiatry, 63,1, 106–113.PubMedCrossRef

Haren, N.E.M. van, Hulshoff Pol, H.E., Schnack, H.G., Cahn, W., Mandl, R.C.W., Collins, D.L., Evans, A.C. & Kahn, R.S. (2007). Focal grey matter changes in schizophrenia across the course of the illness: a 5-year follow-up study.Neuropsychopharmacology, 32,10, 2057–2066.PubMedCrossRef

Hecker, E. (1871). Die hebephrenie: ein beitrag zur klinischen Psychiatrie. Archiv für Pathologische Anatomie undPhysiologie und für Klinische Medizin, 52, 394–429.

Ho, B.-C., Andreasen, N.C., Nopoulos, P., Arndt, S., Magnotta, V. & Flaum, M. (2003). Progressive Structural Brain Abnormalities and Their Relationship to Clinical Outcome: a longitudinal magnetic resonance imaging study early in schizophrenia.Archives of General Psychiatry, 60,6, 585–594.PubMedCrossRef

Holliday, E.G., McLean, D.E., Nyholt, D.R. & Mowry, B.J. (2009). Susceptibility locus on chromosome 1q23-25 for a schizophrenia subtype resembling deficit schizophrenia identified by latent class analysis.Archives of General Psychiatry, 66,10, 1058–1067.PubMedCrossRef

Howes, O.D. & Kapur, S. (2009). The dopamine hypothesis of schizophrenia: version III--the final common pathway.Schizophrenia Buletin, 35,3, 549–562.CrossRef

Hulshoff Pol, H.E. & Kahn, R.S., 2008. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia.Schizophrenia Bulletin, 34,2, 354–366.PubMedCrossRef

Hulshoff Pol, H.E., Schnack, H.G., Mandl, R.C.W., Haren, N.E.M. van, Koning, H., Collins, L., Evans, A.C. & Kahn, R.S. (2001). Focal gray matter density changes in schizophrenia.Archives of General Psychiatry, 58,12, 1118–1125.PubMedCrossRef

Koutsouleris, N., Gaser, C.,Jäger, M., Bottlender, R., Frodl, T., Holzinger, S., Schmitt, G.J.E., Zetzsche, T., Burgermeister, B., Scheuerecker, J., Born, C., Reiser, M., Möller, H.-J. & Meisenzahl, E.M. (2008). Structural correlates of psychopathological symptom dimensions in schizophrenia: a voxel-based morphometric study.NeuroImage, 39,4, 1600–1612.PubMedCrossRef

Kraam, A. (2009). Classic Text No. 77 `Hebephrenia. A contribution to clinical psychiatry’ by Dr. Ewald Hecker in Gorlitz (1871).History of Psychiatry, 20,1, 87–106.PubMedCrossRef

Kraepelin, E. (1919).Dementia-Praecox and Paraphrenia (translated by Barkley RM). New York, NY: Huntington.

Krystal, J.H., Karper, L.P., Seibyl, J.P., Freeman, G.K., Delaney, R., Bremner, J.D., Heninger, G.R., Bowers, M.B. Jr. & Charney, D.S. (1994). Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses.Archives of General Psychiatry, 51,3, 199–214.PubMedCrossRef

Lewis, D.A. (2011). Antipsychotic medications and brain volume: do we have cause for concern?Archives of General Psychiatry, 68,2, 126–127.PubMedCrossRef

Liddle, P.F. (1987). The symptoms of chronic schizophrenia. A re-examination of the positive- negative dichotomy.British Journal of Psychiatry, 151,2, 145–151.PubMedCrossRef

Lieberman, J., Chakos, M., Wu, H., Alvir, J., Hoffman, E., Robinson, D. & Bilder, R. (2001). Longitudinal study of brain morphology in first episode schizophrenia.Biological Psychiatry, 49,6, 487–499.PubMedCrossRef

McGrath, J.A., Avramopoulos, D., Lasseter, V.K., Wolyniec, P.S., Fallin, M.D., Liang, K.-Y., Nestadt, G., Thornquist, M.H., Luke, J.R., Chen, P.-L., Valle, D. & Pulver, A.E. (2009). Familiality of novel factorial dimensions of schizophrenia.Archives of General Psychiatry, 66,6, 591–600.PubMedCrossRef

McIntosh, A.M., Owens, D.C., Moorhead, W.J., Whalley, H.C., Stanfield, A.C., Hall, J., Johnstone, E.C. & Lawrie, S.M. (2011). Longitudinal volume reductions in people at high genetic risk of schizophrenia as they develop psychosis.Biol. Psychiatry, 69,10, 953–958.

Milev, P., Ho, B.-C., Arndt, S., Nopoulos, P. & Andreasen, N.C. (2003). Initial magnetic resonance imaging volumetric brain measurements and outcome in schizophrenia: a prospective longitudinal study with 5-year follow-up.Biological Psychiatry, 54,6, 608–615.PubMedCrossRef

Nenadic, I., Sauer, H. & Gaser, C. (2010). Distinct pattern of brain structural deficits in subsyndromes of schizophrenia delineated by psychopathology.NeuroImage, 49,2, 1153–1160.PubMedCrossRef

Nesvåg, R., Saetre, P., Lawyer, G., Jönsson, E.G. & Agartz, I. (2009). The relationship between symptom severity and regional cortical and grey matter volumes in schizophrenia.Progres in Neuropsychopharmacology & Biological Psychiatry, 33,3, 482–490.CrossRef

Pantelis, C. Yücel, M., Wood, S.J., Velakoulis, D., Sun, D., Berger, G., Stuart, G.W., Yung, A., Philips, L. & McGorry, P.D. (2005).Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia.Schizophrenia Bulletin, 31,3, 672–696.PubMedCrossRef

Peralta, V. & Cuesta, M.J. (2001). How many and which are the psychopathological dimensions in schizophrenia? Issues influencing their ascertainment.Schizophrenia Research, 49,3, 269–285.PubMedCrossRef

Phelan, M., Slade, M., Thornicroft, G., Dunn, G., Holloway, F., Wykes, T., Strathdee, G., Loftus, L., McCrone, P. & Hayward, P. (1995). The Camberwell Assessment of Need: the validity and reliability of an instrument to assess the needs of people with severe mental illness.British Journal of Psychiatry, 167,5, 589–595.PubMedCrossRef

Picard, H., Amado, I., Mouchet-Magas, S., Olié, J.-P. & Krebs, M.-O. (2008). The role of the cerebellum in schizophrenia: an update of clinical, cognitive, and functional evidences.Schizophrenia Bulletin, 34,1, 155–172.PubMedCrossRef

Prasad, K.M.R., Chowdari, K.V., Nimgaonkar, V.L., Talkowski, M.E., Lewis, D.A. & Keshavan, M.S. (2005). Genetic polymorphisms of the RGS4 and dorsolateral prefrontal cortex morphometry among first episode schizophrenia patients.Molecular Psychiatry, 10,2, 213–219.PubMedCrossRef

Rietkerk, T., Boks, M.P.M., Sommer, I.E., Liddle, P.F., Ophoff, R.A. & Kahn, R.S. (2008). The genetics of symptom dimensions of schizophrenia: review and meta-analysis.Schizophrenia Research, 102,1-3, 197–205.PubMedCrossRef

Rodriguez, V.M., Catalina, M.L., García-Noblejas, J.A. & Cuesta, P. (1998). Schizophrenic syndromes and clozapine response in treatment-resistant schizophrenia.Psychiatry Research, 77,1, 21–28.PubMedCrossRef

Salokangas, R.K.R., Honkonen, T., Stengård, E. & Koivisto, A.-M. (2002). Symptom dimensions and their association with outcome and treatment setting in long-term schizophrenia. Results of the DSP project.Nordic Journal of Psychiatry, 56,5, 319–327.PubMedCrossRef

Schnack, H.G., Hulshoff Pol, H.E., Baaré, W.F., Staal, W.G., et al. (2001a). Automated Separation of Gray and White Matter from MR Images of the Human Brain.Neuroimage, 13,1, 230–237.CrossRef

Schnack, H.G., Hulshoff Pol, H.E., Baaré, W.F., Viergever, M.A., et al. (2001b). Automatic Segmentation of the Ventricular System from MR Images of the Human Brain.Neuroimage, 104,1, 95–104.CrossRef

Shenton, M.E., Dickey, C.C., Frumin, M. & McCarley, R.W. (2001). A review of MRI findings in schizophrenia.Schizophrenia Research, 49,1-2, 1–52.PubMedCrossRef

Sled, J.G., Zijdenbos, A.P. & Evans, A.C. (1998). A nonparametric method for automatic correction of intensity nonuniformity in MRI data.IEEE Transactions on Medical Imaging, 17,1, 87–97.PubMedCrossRef

Stinissen, J., Willems, P.J., Coetsier, P. & Hulsman, W.L.L. (1970).Handleiding bij de Nederlandstalige bewerking van de Wechsler adult intelligence scale (W.A.I.S.). Aanvullende normering van de WAIS voor de leeftijdsgroep van 55 tot 64 jaar (WAIS-NL 1970). Amsterdam: Lisse: Swets & Zeitlinger.

Taylor, M.A., Shorter, E., Vaidya, N.A. & Fink, M. (2010). The failure of the schizophrenia concept and the argument for its replacement by hebephrenia: applying the medical model for disease recognition.Acta Psychiatrica Scandinavica, 122,3, 173–183.PubMedCrossRef

Vernon, A.C., Natesan, S., Modo, M. & Kapur, S. (2011). Effect of chronic antipsychotic treatment on brain structure: A serial magnetic resonance imaging study with ex vivo and post-mortem confirmation.Biological Psychiatry, 69,10, 936–944.PubMedCrossRef

Volk, D.W., Eggan, S.M. & Lewis, D.A. (2010). Alterations in metabotropic glutamate receptor 1αand regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia.American Journal of Psychiatry, 167,12, 1489–1498.PubMedCrossRef

Whitford, T.J., Farrow, T.F.D., Gomes, L., Brennan, J., Harris, A.W.F. & Williams, L.M. (2005). Grey matter deficits and symptom profile in first episode schizophrenia.Psychiatry Research, 139,3, 229–238.PubMedCrossRef

Titel: Symptoomdimensiescores zijn geassocieerd met progressieve hersenvolumeveranderingen bij schizofrenie
Auteurs: Mw. drs. G. Collin
mw. dr. N. E. M. van Haren
dr. H. G. Schnack
mw. prof. dr. H. E. Hulshoff Pol
mw. dr. W. Cahn
prof. dr. E. M. Derks
Publicatiedatum: 01-09-2012
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Neuropraxis / Uitgave 4/2012
Print ISSN: 1387-5817
Elektronisch ISSN: 1876-5785
DOI: https://doi.org/10.1007/s12474-012-0021-5

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen

Andere artikelen Uitgave 4/2012

woorden vooraf

Somatisch Onvoldoende verklaarde Lichamelijke Klachten

Werkomgeving en cognitieve veroudering bij leraren: eencase-controle-studie gebaseerd op de Maastrichtse VerouderingsStudie

Elektroconvulsietherapie (ECT) als behandeling voor depressie bij dementerenden?1

signalement